• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MedImmune, Cancer Research U.K. open cancer biotherapeutics lab

MedImmune, Cancer Research U.K. open cancer biotherapeutics lab

September 14, 2015
CenterWatch Staff

MedImmune, the global biologics R&D arm of AstraZeneca, and Cancer Research U.K. have opened a new laboratory focused on the discovery and development of new biologic cancer treatments and diagnostics.

The CRUK-MEDI Alliance Laboratory in Cambridge, U.K., on Granta Park, was opened this week by U.K. Life Sciences Minister George Freeman. The new lab reflects an alliance involving MedImmune, Cancer Research U.K., and its commercialization-and-development subsidiary Cancer Research Technology.

Cancer Research U.K. has provided equipment and operational funding for the lab, and will contribute a portfolio of novel drug targets through its network of principal investigators, while MedImmune will manage the drug discovery process for accepted projects, the partners said.

Researchers from Cancer Research U.K. and MedImmune will collaborate with the goal of discovering and developing new biologics to treat and diagnose cancer. The collaboration is intended to combine Cancer Research U.K.’s cancer biology expertise with MedImmune’s protein-engineering expertise and human antibody phage display libraries.

MedImmune’s phage display technology allows the expression of antibody fragments that retain their ability to interact normally with other molecules. The company says its controlled selection processes of large libraries can identify hundreds of different potential drug candidates to each target protein, with techniques developed to isolate antibodies exhibiting certain traits, such as a desired specific biological function, high potency or cross-reactivity.

“We are driven to engineer the best antibodies and identify which components of cancer make the best targets for treatment. There’s a lot of ground to cover and we’re delighted to be working in partnership to advance this exciting field,” said Maria Groves, Ph.D., head of the CRUK-MEDI Alliance Laboratory and associate director at MedImmune.

“Increasing investment in biotherapeutic treatment forms a key part of Cancer Research U.K.’s research strategy," said Nigel Blackburn Ph.D., director of drug development at Cancer Research U.K.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing